Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions.

导出 LinkOut

翻译打印收藏纠错

第一作者： Hiroki,Ishihara

第一单位： Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

作者： Hiroki,Ishihara ^[1] ; Hironori,Fukuda ^[1] ; Toshio,Takagi ^[1] ; Tsunenori,Kondo ^[2] ; Hidekazu,Tachibana ^[2] ; Kazuhiko,Yoshida ^[1] ; Junpei,Iizuka ^[1] ; Hirohito,Kobayashi ^[2] ; Hideki,Ishida ^[1] ; Kazunari,Tanabe ^[1]

作者单位： Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. ^[1] Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan. ^[2]

关键词 PD-1 RCC immune checkpoint inhibitor kidney cancer targeted therapy

主题词癌, 肾细胞(Carcinoma, Renal Cell);人类(Humans);日本(Japan);肾肿瘤(Kidney Neoplasms);回顾性研究(Retrospective Studies);治疗结果(Treatment Outcome)

DOI 10.1111/iju.14412

PMID 33159426

发布时间 2021-04-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交